Literature DB >> 11956854

Febrile urinary tract infection: Escherichia coli susceptibility to oral antimicrobials.

Noemia P Goldraich1, Angélica Manfroi.   

Abstract

Empirical treatment is indicated for young children with febrile urinary tract infection (UTI). In this clinical setting, oral antibiotics are as safe and effective as intravenous therapy. The aim of this study was to investigate in children with febrile UTI whether there were longitudinal changes in the prevalence of bacteria and in the pattern of Escherichia coli susceptibility to oral antimicrobial agents. Two hundred and eighty-seven positive urine cultures from children (1 month to 12 years) with febrile UTI collected over three periods (1986-1989, 1990-1991, and 1997) were studied. E. coli was the most-prevalent microorganism in all three study-periods ( n=228). The susceptibility pattern of E. coli to nitrofurantoin (92%, 95%, 94%) and nalidixic acid (85%, 92%, 95%) did not present any statistically significant differences ( P>0.05) over time. There was a significant increase ( P<0.05) in E. coli susceptibility to cephalexin (65%, 54%, 81%). The E. coli susceptibility to trimethoprim-sulfamethoxazole (40%, 85%, 40%) behaved differently. Initially there was a significant rise ( P<0.05), followed by a significant decrease ( P<0.05). Empirical oral treatment with nitrofurantoin or nalidixic acid can safely be started in children with febrile UTI seen in the Emergency Department, Hospital de Clínicas de Porto Alegre, Brazil.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11956854     DOI: 10.1007/s00467-001-0808-8

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  14 in total

1.  Oral antibiotics for febrile urinary tract infections.

Authors:  Arvind Bagga; Mukta Mantan
Journal:  Pediatr Nephrol       Date:  2003-04-05       Impact factor: 3.714

2.  Antimicrobial susceptibility of pediatric uropathogens in Thrace, Greece.

Authors:  Elpis Mantadakis; Aggelos Tsalkidis; Maria Panopoulou; Spyridon Pagkalis; Gregory Tripsianis; Mathew E Falagas; Mathew Falagas; Sophia Kartali-Ktenidou; Athanassios Chatzimichael
Journal:  Int Urol Nephrol       Date:  2010-06-04       Impact factor: 2.370

3.  Elevated levels of secretory immunoglobulin A (sIgA) in urinary tract infections.

Authors:  Sudha S Deo; Avinash K Vaidya
Journal:  Indian J Pediatr       Date:  2004-01       Impact factor: 1.967

4.  Long-term resistance trends of uropathogens and association with antimicrobial prophylaxis.

Authors:  Maria Bitsori; Sofia Maraki; Emmanouil Galanakis
Journal:  Pediatr Nephrol       Date:  2013-12-21       Impact factor: 3.714

5.  Vesicoureteric reflux in Kuwaiti children with first febrile urinary tract infection.

Authors:  Mohamed Zaki; Ghalia Al Mutari; Mona Badawi; Dina Ramadan; Emad Al deen Hanafy
Journal:  Pediatr Nephrol       Date:  2003-07-18       Impact factor: 3.714

6.  Management of urinary tract infections.

Authors:  Pankaj Hari; Mukta Mantan; Arvind Bagga
Journal:  Indian J Pediatr       Date:  2003-03       Impact factor: 1.967

7.  Antibiotic resistance of urinary tract pathogens and rationale for empirical intravenous therapy.

Authors:  Maria Haller; Matthias Brandis; Reinhard Berner
Journal:  Pediatr Nephrol       Date:  2004-06-18       Impact factor: 3.714

8.  DMSA study performed during febrile urinary tract infection: a predictor of patient outcome?

Authors:  V Camacho; M Estorch; G Fraga; E Mena; J Fuertes; M A Hernández; A Flotats; I Carrió
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02-03       Impact factor: 9.236

9.  Febrile urinary tract infection in children: ampicillin and trimethoprim insufficient as empirical mono-therapy.

Authors:  Martina Prelog; Daniela Schiefecker; Manfred Fille; Reinhard Wurzner; Andrea Brunner; Lothar Bernd Zimmerhackl
Journal:  Pediatr Nephrol       Date:  2008-01-12       Impact factor: 3.714

10.  Cephamycin resistance in clinical isolates and laboratory-derived strains of Escherichia coli, Nova Scotia, Canada.

Authors:  Brian Clarke; Margot Hiltz; Heather Musgrave; Kevin R Forward
Journal:  Emerg Infect Dis       Date:  2003-10       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.